Browse studies

Find your next paid study

1 recruiting study matching your filters

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications …

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more

Mayo ClinicNCT06712810